UK HealthTech startup Medopad has secured $28m (£19.6m) at the first close of its Series A round featuring investment from China’s NWS Holdings.
The company, which leverages artificial intelligence as part of its data-capture platform offering, seeks to connect patients and healthcare professionals in real-time.
Medopad is planning to raise a total of $120m (£84m) in what would potentially become of the biggest early-stage raises for a UK firm.
The firm’s primary customers include hospitals, pharmaceutical companies, insurance providers and governments.
Medopad says it has already entered into strategic partnerships with leading healthcare, technology and academic institutions, including Royal Free NHS Hospital, Ping An Good Doctor, China Resources, Tencent, HP, Lenovo, Johns Hopkins University, Imperial College Health Partners and Peking University.
Dan Vahdat, CEO of Medopad, commented: “We now have several amazing strategic investors in the business, which is a great achievement for us as we gear for significant growth and scale our business. Managing population health is one of the greatest challenges for governments across the world. As such, the investment appetite for solutions that address and manage this concern is substantial. We are proud to be at the forefront of solving this problem and supporting people around the world.”